GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist ...

Respiratory Virus Hospitalization Surveillance Network (RESP-NET) is made up of three networks that monitor COVID-19, ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Respiratory viruses can remain hidden in immune cells in the lungs long after the initial symptoms of an infection have ...

In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...

Immunization appointments are now open for eligible Albertans. As of Monday (Oct. 7) both COVID-19 and influenza immunization ...

Illness from RSV is considered an infectious disease, usually leading to an infection of the upper respiratory tract but ...

Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.